Calpain inhibition prevents amyloid-beta-induced neurodegeneration and associated behavioral dysfunction in rats
Ivica Granic1, Csaba Nyakas, Paul G M Luiten
1Molecular Neurobiology, University of Groningen, Haren, The Netherlands.
Abstract:
Amyloid-beta (Abeta) is toxic to neurons and such toxicity is - at least in part - mediated via the NMDA receptor. Calpain, a calcium dependent cystein protease, is part of the NMDA receptor-induced neurodegeneration pathway, and we previously reported that inhibition of calpain prevents excitotoxic lesions of the cholinergic nucleus basalis magnocellularis of Meynert. The present study reveals that inhibition of calpain is also neuroprotective in an in vivo model of Abeta oligomer-induced neurodegeneration in rats. Abeta-induced lesions of the nucleus basalis induced a significant decrease in the number of cholinergic neurons and their projecting fibers, as determined by analysis of choline-acetyltransferase in the nucleus basalis magnocellularis and cortical mantle of the lesioned animals. Treatment with the calpain inhibitor A-705253 significantly attenuated cholinergic neurodegeneration in a dose-dependent manner. Calpain inhibition also significantly diminished the accompanying neuroinflammatory response, as determined by immunohistochemical analysis of microglia activation. Administration of beta-amyloid markedly impaired performance in the novel object recognition test. Treatment with the calpain inhibitor, A-705253, dose-dependently prevented this behavioral deficit. In order to determine whether pre-treatment with the calpain inhibitor is necessary to exhibit its full protective effect on neurons we induced Abeta toxicity in primary neuronal cultures and administered A-705253 at various time points before and after Abeta oligomer application. Although the protective effect was higher when A-705253 was applied before induction of Abeta toxicity, calpain inhibition was still beneficial when applied up to 1h post-treatment. We conclude that inhibition of calpains may represent a valuable strategy for the prevention of Abeta oligomer-induced neuronal decline and associated cognitive deterioration.
Insights
Inhibition of calpain, a calcium-dependent protease, protects neurons from amyloid-beta (Abeta) toxicity. This neuroprotection strategy also reduces neuroinflammation and cognitive deficits associated with Abeta exposure.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Amyloid-beta (Abeta) peptides are implicated in neuronal toxicity, partly through NMDA receptor activation.
- Calpain, a calcium-dependent cysteine protease, is a key component of NMDA receptor-mediated neurodegeneration pathways.
Purpose of the Study:
- To investigate the neuroprotective effects of calpain inhibition against amyloid-beta oligomer-induced neurodegeneration in vivo.
- To assess the impact of calpain inhibition on neuroinflammation and cognitive function in an animal model.
Main Methods:
- Utilized an in vivo rat model of amyloid-beta oligomer-induced neurodegeneration.
- Administered the calpain inhibitor A-705253 and assessed cholinergic neuron survival, fiber density, and microglia activation.
- Evaluated cognitive performance using the novel object recognition test.
- Conducted in vitro experiments on primary neuronal cultures to determine optimal timing of inhibitor administration.
Main Results:
- Calpain inhibition with A-705253 dose-dependently attenuated cholinergic neurodegeneration and preserved neuronal fibers.
- Calpain inhibition significantly reduced microglial activation, indicating a diminished neuroinflammatory response.
- Amyloid-beta administration impaired cognitive function, which was dose-dependently prevented by A-705253 treatment.
- Calpain inhibition provided neuroprotection even when administered up to 1 hour after amyloid-beta exposure.
Conclusions:
- Calpain inhibition is a promising therapeutic strategy for preventing amyloid-beta-induced neurodegeneration.
- Targeting calpains may mitigate associated cognitive decline and neuroinflammation.
- The therapeutic window for calpain inhibition extends beyond pre-treatment, offering potential clinical applicability.
More Related Videos
04:41Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
